Background: Chronic ethanol (EtOH) exposure has been found to inhibit adult hippocampal neurogenesis in multiple models of alcohol addiction. However, acute EtOH inhibition of adult neurogenesis is not well studied. Although many abused drugs have been found to inhibit adult neurogenesis, few have studied cannabinoids or cannabinoids with EtOH, although human use of both together is becoming more common. We used an acute binge alcohol drinking model in combination with select cannabinoid receptor agonists and antagonists to investigate the actions of each alone and together on hippocampal neurogenesis.
T HE EXTENSIVE USE of cannabis is likely to increase exposure of cannabinoids and alcohol during social and other occasions. The endocannabinoid (eCB) system in brain contributes to pain, appetite, and cognition (Dalton and Howlett, 2012) and is known to disrupt hippocampusdependent behavior (Katona and Freund, 2012) . It includes 2 key receptors, for example, cannabinoid 1 receptor (CB1R) and cannabinoid 2 receptor (CB2R) that respond to plant cannabinoids as well as eCB agonists. eCB signaling can be modified by pharmacological inhibition of synthetic or catabolic breakdown enzymes. For example, the administration of the URB597 (eCB degrading enzyme, FAAH [fatty acid amide hydrolase] inhibitor) into the prefrontal cortex has been shown to increase alcohol intake in rodents (Basavarajappa et al., 2006; Hansson et al., 2007; Vinod et al., 2008) . However, discrepancies in animal model findings confound the effects of the modulators of eCB signaling on alcohol consumption (Serrano and Parsons, 2011) . FAAH inhibition has also been reported to reduce alcohol withdrawal in rats (Cippitelli et al., 2008) . eCBs are known to have major actions on glutamatergic signaling, similar to ethanol (EtOH) and to increase fetal alcohol-induced neurodegeneration (Basavarajappa, 2015) . Alternatively, eCB has been postulated to be neuroprotective in EtOH-induced neural progenitor cell (NPC) culture studies (Bandiera et al., 2014; Galve-Roperh et al., 2013; Katona and Freund, 2012) . The eCB and EtOH responses vary across cells in part due to differences in CB1R and CB2R expression, with CB1R the predominant adult brain CB receptor, with CB2R postulated to be expressed in microglia. Previous studies have shown extensive involvement of eCB signaling in brain development and found eCB signals interact with EtOH-induced changes in neurons and glia that contribute to fetal alcohol-induced pathology (Basavarajappa, 2015) . These studies prompted an investigation of how EtOH and eCB might interact to impact NPC and neurogenesis in adult brain.
A substantial literature across multiple species has investigated the formation of new neurons, for example, neurogenesis, in adult brain, with a focus on hippocampal dentate gyrus (DG). Multiple models of EtOH exposure, particularly, chronic binge models have linked EtOH inhibition of neurogenesis to alcohol-induced neurodegeneration (Crews and Nixon, 2009) . Further, several studies have well documented that alcohol-induced neurodegeneration resulted in cognitive disorders due to apoptosis of neuronal cells and/or the decrease in adult brain neurogenesis following an acute and chronic alcohol consumption (Nixon and Crews, 2004) . More recent studies have associated a persistent loss of both dorsal and ventral hippocampal neurogenesis following adolescent EtOH exposure with adult cognitive dysfunction (Vetreno and Crews, 2015) . Alternatively, in aged mouse brain, activation of CB1R and/or CB2R or the inhibition of the eCB anandamide degrading enzyme FAAH promotes neural proliferation and neurogenesis that is blocked by the CB1R antagonist SR141716 (SR1) (Aguado et al., 2005; Goncalves et al., 2008) . This is consistent with studies suggesting CB1R activation promotes neuronal differentiation, maturation, and resistance to brain injury (Compagnucci et al., 2013; Fowler et al., 2010; Marsicano et al., 2003; Parmentier-Batteur et al., 2002) . Recently, selective CB2R activation has also been shown to protect deficits in neurogenesis, without the undesired psychoactive effects of neuronal CB1R activation (Avraham et al., 2014; Palazuelos et al., 2012; Rom and Persidsky, 2013; Stella, 2010) . Thus, the effects and mechanism of the activation of eCB signaling on alcohol consumption and/or the EtOH-mediated effects in brain are not clear.
Most studies of EtOH-induced changes in adult neurogenesis have investigated chronic EtOH treatment; however, human use of both cannabis and alcohol is likely to be combined acute exposures. To understand whether combined acute CB receptor activation and acute binge EtOH altered adult hippocampal neurogenesis, we employ known CB receptor agonists, antagonists, and a FAAH inhibitor combined with an acute binge EtOH treatment and determine neurogenesis after 3 and 24 hours. We report here that exogenous activation of CB1R and inhibition of eCB catabolism alone or in combination with binge EtOH resulted in robust inhibition of neurogenesis in hippocampal DG that coincides with a marked increase in markers of activated caspase-3 (a marker of cell death). Further, cotreatment with CB1R antagonists (AM251 or SR1), but not CB2R, blocks both EtOH and CB1R agonist (alone or in combination)-induced inhibition of adult neurogenesis and increased expression of cell death markers. These findings suggest EtOH and CB1Rs interact to inhibit adult neurogenesis during acute alcohol intoxication.
MATERIALS AND METHODS

Drugs
ACEA (arachidonoyl-2
0 -chloroethylamide), JZL195 (4-[(3-phenoxyphenyl) methyl]-1-piperazinecarboxylic acid 4-nitrophenyl ester), SR1 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide), AM251 (N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide), and HU-308 (4-[4-(1,1-dimethylheptyl)-2,6-dimethoxyphenyl]-6,6-dimethyl-bicyclo [3.1.1] hept-2-ene-2-methanol), were purchased from Cayman Chemical (Ann Arbor, MI).
Animals and Drugs Treatment
Adult male Wistar rats (~3 months of age; 280 to 320 g) were acclimated to the animal facility for 7 days at the University of North Carolina at Chapel Hill and randomly assigned to treatment ; n = 6). Treatment with EtOH, ACEA alone, or in combination (ACEA + EtOH) significantly reduced DCX + IR relative to controls, F(3, 87) = 47.72, **p < 0.01 for EtOH and ***p < 0.001 for ACEA and (ACEA+EtOH).
groups (n = 6 to 8 subject per group) prior to the onset of experimentation. All animals were pair housed standard housing cages (GR900; floor area: 904 cm 2 ; Tecniplast, West Chester, PA) in a temperature-(20°C) and humidity-controlled (30 to 70%) vivarium on a 12-h/12-h light/dark cycle (light onset at 0700 hours) and provided ad libitum access to food and water. Experimental procedures were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill and conducted in accordance with National Institutes of Health regulations for the care and use of animals in research.
For the EtOH experiment, subjects received either a single dose of EtOH (5.0 g/kg, intragastrically [i.g.], 25% w/v in H 2 O) at a volume of 0.025 ml/g body weight to produce a blood EtOH level of 100 to 160 mg% as previously described or a comparable volume of vehicle.
For the cannabinoid experiments, all drugs were purchased from Cayman Chemical and stock solutions prepared as recommended by the manufacturer. SR1 (1.0 mg/kg, intraperitoneally [i.p.]) and AM251 (1.0 mg/kg, i.p.) were supplied as a solid and dissolved in minimum volume of EtOH to prepare a stock solution (30 and 14 mg/ml, respectively). JZL 195 crystal was dissolved in DMSO to produce a stock solution of 1.25 mg/ml and administered at 3.0 mg/kg, i.p. CB1R agonist ACEA (3.0 mg/kg, i.p.) was supplied in methyl acetate and the organic solvent evaporated under nitrogen and dissolved in EtOH to produce a 20 mg/ml stock solution. The CB2R agonist HU-308 was administered at 15 mg/kg, i.p. All drugs were further diluted using a vehicle consisting of 5.0% EtOH, 5.0% emulphor (alkamuls-620; Rhone-Poulenc, Princeton, NJ), and 90% saline (0.9%; EtOH: emulphor: saline 1:1:18; Gamage et al., 2014; Kinsley et al., 2013; Wiebelhaus et al., 2015; Wiley et al., 2006) . All cannabinoid compounds were administered i.p. at a volume of 10 ll/g body mass. All solutions were warmed to room temperature prior to injection. The control group received a comparable i.p. injection of the same vehicle. The doses of the drugs were chosen based on the literature search for the in vivo doses of the compounds used in other studies (Tsvetanova, 2006; Walsh et al., 2015; Wiley et al., 2006; Wilson et al., 2006) . CB1R antagonists, SR1 and AM251, were administered 30 minutes prior to EtOH and/or CB1R agonist ACEA or JZL195 administration in all experiments. The amount of EtOH present in the vehicle was insignificant after drug dilution. Animals were sacrificed 3 or 24 hours after the conclusion of treatment.
Animal Perfusion, Tissue Preparation, and Immunohistochemistry
Perfusion and brain tissue preparation and immunohistochemistry procedures were performed as described early (Vetreno and Crews, 2015) . Briefly, at the end of each experiment, animals were euthanized with sodium pentobarbital (100 mg/kg, i.p.) and transcardially perfused with 0.1 M phosphate-buffered saline (PBS; pH 7.4) followed by 4.0% paraformaldehyde in PBS. Brains were excised quickly and postfixed in 4.0% paraformaldehyde for 24 hours at 4°C followed by 4 days of fixation in 30% sucrose solution. Hippocampal tissue sections were sampled between bregma À2.12 mm and À3.80 mm according to the atlas of Paxinos and Watson (1998) yielding tissue for analysis of the DG throughout the dorsal hippocampus. Coronal sections (1:12 series) of 40 lm were collected on a vibrating microtome (Leica VT1000S; Leica Biosystems Inc., Buffalo Grove, IL) and stored in cryoprotectant (30% glycol/30% ethylene glycol in PBS) at À20°C until immunohistochemical labeling. Free-floating sections (every 12th section) were processed for immunohistochemistry following standard procedures for DAB detection. Briefly, tissue was washed in 0.1 M PBS, incubated in 0.3% H 2 O 2 in PBS to inhibit endogenous peroxidases, and incubated in a blocking solution (PBS, 0.1% Triton-X and 4% goat serum; MP Biomedicals, Solon, OH) for 1 hour. Tissue was then incubated at 4°C for 24 hours in primary antibody (anti-doublecortin [DCX]; 1:1,000 or anti-Ki67; 1:500 from Abcam, Cambridge, MA) diluted in blocking solution. Sections were then washed with PBS, incubated in biotinylated goat anti-rabbit IgG for 1 hour (Vector Laboratories, Burlingame, CA), and incubated for 1 hour in avidin-biotin complex solution (Vectastain ABC Kit; Vector Laboratories). The chromogen, nickel-enhanced diaminobenzidine (Sigma-Aldrich, St. Louis, MO), was used to visualize immunoreactivity. Tissue was mounted onto slides, dehydrated, and cover-slipped. Negative control for nonspecific binding was conducted on separate sections employing the abovementioned procedures omitting the primary antibody.
For cleaved caspase staining, standard immunofluorescence procedure was followed. The free-floating sections (every 12th section) were washed in 0.1 M PBS for 15 minutes thrice. The tissues were then transferred into permeabilization buffer (0.2% Triton X-100 in PBS) and incubated for 2 hours at room temperature, blocked in a blocking solution (10% goat serum, 0.05% Triton X-100 and PBS) for 2 hours at 37°C. Sections were then incubated in cleaved caspase primary antibody (Cell Signaling # 9661 [Cell Signaling Technology, Danvers, MA]; for 48 hours at 4°C followed by washing in wash buffer (PBS, 0.01% Triton X-100, 1% goat serum). This cleaved caspase-3 (CC3 [Cell Signaling Technology]; Asp175) antibody has been validated by the manufacturer using Western blot as well as immunohistochemistry. It detects a large fragment (17/ 19 kDa) of activated caspase-3 resulting from cleavage adjacent to Asp175 of the inactive globulin CC3. The antibody does not recognize inactive full-length caspase-3 or other cleaved caspases in tissue sections (Gown and Willingham, 2002; Kaiser et al., 2008; Olney et al., 2002; Yang et al., 2017) . The sections were then incubated in Alexa Fluor 488-Goat Anti-Rabbit IgG (Jackson Immunoresearch, West Grove, PA) for 48 hours at 4°C followed by washing in PBS thrice for 15 minutes each. After the washes, the sections were mounted on glass slides using Vectashield mounting media containing DAPI (Vector Laboratories). The slides were cover-slipped; edges sealed with nail polish and let dry. The slides were then stored at 4°C and the images taken using a fluorescence microscope.
Image Acquisition and Analysis
For this entire study, Bioquant Nova Advanced Image Analysis (R&M Biometric, Nashville, TN) was used for image capture and analysis. Images were captured with an Olympus BX50 microscope (Center Valley, PA) and Sony DXC-390 video camera (Sony Corporation of America, New York, NY). Quantification of the sections was carried out following the method described early (Vetreno and Crews, 2015) using an Olympus microscope equipped with an Olympus UPlan objective (109/0.30). Assessment of DCX was performed throughout the dorsal and ventral hippocampal DG according to the atlas of Paxinos and Watson (1998) . The total number of Ki67 and CC3 immunoreactive cells was quantified throughout the dorsal hippocampus, and data are expressed as cells per mm 2 .
Statistical Analysis
Statistical analyses were performed using GraphPad Prism software (version 5.0; GraphPad Software, La Jolla, CA) and 1-way analysis of variance, and post hoc analyses were performed using Bonferroni test. Data are expressed as mean AE SEM, and significance was defined as p ≤ 0.05. 
RESULTS
Neurogenesis is Reduced Following Acute EtOH and Cannabinoid Treatment
To determine how EtOH and cannabinoid effect adult neurogenesis, we assessed DCX (DCX, a protein expressed uniquely in developing, but not mature neurons) + IR cells in DG. Acute EtOH exposure decreased DCX + IR by 48% (**p < 0.01) (Fig. 1A) . We then tested ACEA, a selective agonist to the CB1R (Hillard et al., 1999) , and found a slightly greater significant decrease in DCX + IR (60%,***p < 0.001). Surprisingly, combined (ACEA + EtOH) treatment decreased DCX + IR by 63% (***p < 0.001) although additive effects were not observed. These findings indicate both acute EtOH and CB1R agonists can inhibit adult hippocampal neurogenesis.
To further investigate our surprising discovery of CB1R inhibition of adult neurogenesis, rats were treated with the CB1R selective antagonist SR1 prior to treatment with ACEA or the vehicle. As shown in Fig. 2 , similar to the experiment in Fig. 1 , CB1R agonist treatment reduced DCX + IR by about 59% (***p < 0.001), whereas CB1R antagonist SR1 cotreatment blocked the ACEA-induced reduction in DCX + IR, while SR1 had no effect alone.
Next, we used JZL195, an inhibitor of FAAH and monoacylglycerol lipase, the 2 principal hydrolytic enzymes of the endogenous eCBs anandamide and 2 arachidonoylglycerol, respectively. Rats treated with JZL195 alone had a 43% decrease in DCX + IR (***p < 0.001) consistent with increases in endogenous eCB leading to reductions in neurogenesis. The combination of JZL195 with SR1 reversed JZL195-induced decrease in DCX + IR. Interestingly, rats sacrificed 24 hours after EtOH or ACEA treatment did not show changes in DCX + IR (Fig. 3) and this is consistent with transient actions possibly coincident with peak drug levels. The CB2R agonist HU-308 did not affect DCX + IR at either 3 or 24 hours (Fig. 3) . These results indicate CB1R agonist-induced transient (3 hours after treatment) decrease in DCX + IR is mediated by the CB1R and thereby can be blocked by CB1R antagonist, SR1.
CB1R Antagonist Reversed EtOH-Induced Inhibition of Hippocampal Adult Neurogenesis
To determine the impact of CB1R antagonists on acute EtOH inhibition of neurogenesis, we investigated 2 different CB1R antagonists, AM251 and SR1. Surprisingly, both Fig. 4A,B) and SR1 (Fig. 4C,D) treatments prior to EtOH prevented the EtOH-induced decrease in DCX + IR. Similar to SR1 alone in Fig. 2B , AM251 did not produce any effect on DCX + IR alone (Fig. 4B) . These findings suggest CB1R antagonists can protect against acute binge EtOH-induced decreases in DCX + IR neurogenesis.
AM251 (
Increased Cell Death, But Not NPC Proliferation by Acute Ethanol and/or eCB Receptor Drugs
Our findings that ACEA, JZL195, and EtOH reduce DCX + IR suggests neurogenesis is reduced as DCX identifies NPC committed to a neuronal differentiation. To better understand the mechanisms, we assessed hippocampal DG NPC proliferation using Ki67 + IR and a marker of cell death, activated CC3 + IR where NPC are located in hippocampal DG. Ki67 is an endogenous cell cycle protein expressed in actively dividing cells from G1-phase through M-phase and is commonly used to study cell proliferation (Scholzen and Gerdes, 2000) . Previous studies have found acute EtOH decreases the formation of BrdU + NPC 5 hours after EtOH (5 g/kg, i.g. EtOH; similar to dose used here) exposure decreased proliferation (Nixon and Crews, 2002) . To our knowledge, this is the first acute EtOH exposure study or acute ACEA exposure alone or in combination study assessing Ki67 + IR in hippocampal DG. We did not find any significant change in Ki67 + IR following acute EtOH (p > 0.05), acute ACEA (p > 0.05), or HU-308 (p > 0.05) at 3 or 24 hours (Fig. 5) . The lack of change in Ki67 + IR after acute EtOH treatment contrasts with longlasting decreases in NPC proliferation following adolescent intermittent chronic EtOH exposure (Liu and Crews, 2017) . These findings suggest NPC proliferation is not the mechanism of decreased DCX + IR. We next assessed a marker of cell death pathways, activated CC3. Caspase-3, known as the executioner caspase, is formed as an inactive zymogen procaspase that does not have protease activity. Activation of CC3 can occur through by both extrinsic (death ligand) and intrinsic (mitochondrial depolarization) cell death pathways. Controls show a basal level of cell death in DG as many progenitors do not mature to neurons under control conditions. Interestingly, we found CB1R agonist ACEA significantly increased the number of CC3 + IR (cells/mm (**p < 0.01) (Fig. 6) . EtOH also increased CC3 + IR cells by 68% (**p < 0.01). Similar to our findings on DCX + IR, the CB1R antagonist SR1 alone did not change CC3 + IR cells, but blocked both the ACEA and EtOH-induced increase in CC3 + IR cells. These findings suggest both acute EtOH and ACEA increase the cell death marker, CC3 + IR, through a mechanism sensitive to SR1 and thus mediated by the CB1R.
DISCUSSION
Although extensive studies have investigated eCB involvement in brain development and neuroprogenitors in vitro and in vivo (Prenderville et al., 2015) , to our knowledge this is the first study to directly investigate the impact of CB1R agonist ACEA and eCB enhancing JZL195 on expression of the hippocampal neurogenesis marker DCX. We found that acute EtOH treatment and acute ACEA and JZL195 treatment reduce DCX + IR consistent with the reduced adult hippocampal neurogenesis. Previous studies have found an acute EtOH binge exposure reduces BrdU labeling of adult NPC in hippocampus (Nixon and Crews, 2002) and reduces DCX + IR in adolescent rat brain after acute EtOH treatment . These findings are consistent with chronic EtOH exposure-induced inhibition of neurogenesis (Nixon et al. 2008) . We found ACEA, the direct CB1R agonist and JZL195, an inhibitor of endogenous eCB metabolism known to increase endogenous levels of eCB agonists, decrease DCX + IR transiently at 3 hours after treatment, but not 24 hours after treatment. Further, the reduction in DCX + IR by both ACEA and JZL195 was blocked by the CB1R antagonist SR1 consistent with the CB1R mediating the reduction in DCX + IR. We did not find an effect of the CB2R agonist, HU-308, on DCX + IR at either 3 or 24 hours consistent with a selective CB1R acute response. Similarly, acute EtOH inhibition of DCX + IR was found after 3 hours of exposure, but not 24 hours after EtOH treatment, consistent with a transient loss of neurogenesis during intoxication. Surprisingly, we found CB1R antagonists, for example, SR1 and AM251, blocked acute EtOH inhibition of DCX + IR, without any effect of the antagonists alone. Antagonists to CB1R blocked JZL195-mediated decreases in DCX + IR consistent with eCB reducing neurogenesis through CB1Rs. Similarly, reversal of acute EtOH inhibition of DCX + IR by CB1R antagonists is consistent with EtOH increasing endogenous eCB that activate CB1Rs resulting decrease in DCX + IR (Fig. 7) . Our studies find robust acute inhibition of DCX + IR by both EtOH and ACEA. As both are blocked by CB1R antagonists, the simplest interpretation of these data is that acute EtOH and ACEA share a common mechanism requiring CB1Rs. DCX + IR NPC are formed from dividing NPC and many do not survive to mature DG neurons so we determined NPC proliferation with Ki67 and cell death using CC3. We found CC3, but not Ki67, was increased by acute EtOH and ACEA, and both were blocked by SR1, consistent with CB1Rs increasing activation of caspase-3, a marker of cell death, that reduces DCX + IR NPC. Hippocampal neurogenesis has been linked to both cognition and mood, and hippocampal NPC mature to granule cell neurons over about a month. The acute reductions in DCX + IR during intoxication with acute alcohol and/or cannabinoid CB1R agonists suggest these agents alone and in combination could disrupt cognition and mood acutely and perhaps later due to a lack of new neurons from maturing NPC. These studies suggest that acute EtOH and cannabinoids alone and together acutely reduce adult hippocampal neurogenesis involving CB1Rs (Fig. 7) .
Many studies have found expression of endogenous cannabinoids as well as CB1R and CB2R in both in vivo and in vitro models of NPC neurogenesis; however, responses vary across models and primarily involve changes in NPC proliferation (Prenderville et al., 2015) which differs from our finding of no change in Ki67 + IR, a marker identifying dividing NPC in adult DG. Previous studies in SpragueDawley rats using BrdU labeling find a 40% decrease in newly formed BrdU + IR progenitors 5 hours after acute EtOH (5 g/kg, i.g.) (Nixon and Crews, 2002) , but in our study in Wistar rats, we found no change in Ki67 3 hours after EtOH treatment. These are 2 different methods for assessment of progenitor proliferation, and there are many more BrdU + IR cells/DG which are incorporated in Sphase, than the Ki67 + IR cells, which label all actively dividing cells (Peng et al., 2017) . Thus, EtOH may impact progenitor proliferation that we did not detect with Ki67 + IR. Our findings that EtOH and CB1R activation reduced DCX + IR and increased CC3 + IR are consistent with previous studies in postnatal day 7 mice (Subbanna et al., 2013) . Acute EtOH treatment of P7 mice led to a rapid induction of the synthetic enzymes producing anandamide and CB1Rs as well as a marked increase in hippocampal CC3, the cell death marker, that was blocked by SR1 and not observed in the transgenic mouse lacking CB1R. These studies suggested that in neonates with immature neuron, EtOH and CB1R activation of caspase-3 and inhibition of the kinase ERK contribute to long-lasting brain dysfunction (Subbanna et al., 2013) . Interestingly, transgenic mice lacking CB1Rs show a slight decrease in basal neurogenesis (Dubreucq et al., 2010; Wolf et al., 2010) . Our study in rats did not find an effect of SR1, the CB1R antagonist, treatment consistent with previous studies, finding no effect on hippocampal DG neurogenesis (Jin et al., 2004) and consistent with little or no basal eCB action on neurogenesis. We were surprised that SR1 and another CB1R antagonist blocked EtOH inhibition of neurogenesis, suggesting release of eCB signals activating CB1Rs that in turn increase cell death in DCX + progenitors. Other studies have found chronic tetrahydrocannabinol reduces neurogenesis (Wolf et al., 2010 ) consistent with our acute CB1R agonist reduction in DCX + IR. Our finding that JZL195 which increases endogenous eCB is blocked by SR1 is consistent with EtOH increasing eCB that acts on CB1Rs to reduce neurogenesis. The mechanisms of acute EtOH and CB1R agonist inhibition of neurogenesis and increased CC3 need additional studies to fully understand how CC3 is activated in NPC and other cells.
Previous studies have linked EtOH-mediated inhibition of neurogenesis to activation of NFkB and increases in neuroimmune gene expression (Koo et al., 2010; Zou and Crews, 2012) . Our findings of decreased DCX + IR, a lack of Ki67 + IR change, and increased CC3 + IR suggest neurogenesis is decreased primarily through a decrease in survival of newly generated neurons. However, there are multiple potential mechanisms by which acute EtOH exposure and eCB might impact DCX + IR and CC3 + IR. This is the first report of specific CB1R agonists on DCX + IR and CC3 + IR. Additional studies are needed to determine whether this interaction involves changes in proinflammatory cytokines and/or other mechanisms. Further, our increase in CC3 + IR may reflect increased cell death in mature DG neurons or other cells as some CC3 + IR cells are outside the DG. Our findings on CB1R agonists and antagonists do not directly translate to marijuana, as it contains a complex mixture of CB agonist and cannabidiol, which is not a CB agonist and protects against EtOHinduced neurodegeneration and loss of neurogenesis (Liput et al., 2013) . Our studies presented here support the hypothesis that EtOH inhibition of neurogenesis is linked to activation of CB1Rs through eCB release. However, the CB1R and acute alcohol-induced reduction in neurogenesis is transient, suggesting multiple cycles may be necessary for any actions related to development of AUD.
